For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Repligen Corp (NASDAQ: RGEN) was $117.07 for the day, down -4.70% from the previous closing price of $122.85. In other words, the price has decreased by -$4.70 from its previous closing price. On the day, 1.15 million shares were traded. RGEN stock price reached its highest trading level at $122.725 during the session, while it also had its lowest trading level at $116.76.
Ratios:
Our analysis of RGEN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 54.93. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 6.79. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.27.
On June 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $150.
Wolfe Research Upgraded its Peer Perform to Outperform on April 29, 2025, while the target price for the stock was maintained at $160.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 15 ’25 when Hunt Anthony sold 26,447 shares for $123.71 per share. The transaction valued at 3,271,688 led to the insider holds 109,854 shares of the business.
Hunt Anthony bought 26,447 shares of RGEN for $3,394,208 on May 15 ’25. On Mar 17 ’25, another insider, Hunt Anthony, who serves as the Director of the company, sold 26,756 shares for $152.51 each. As a result, the insider received 4,080,663 and left with 136,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 6577355264 and an Enterprise Value of 6563824640. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.76 while its Price-to-Book (P/B) ratio in mrq is 3.31. Its current Enterprise Value per Revenue stands at 9.739 whereas that against EBITDA is 54.916.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.05, which has changed by -0.27587062 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is -5.21%, while the 200-Day Moving Average is calculated to be -16.07%.
Shares Statistics:
RGEN traded an average of 821.10K shares per day over the past three months and 1313460 shares per day over the past ten days. A total of 56.18M shares are outstanding, with a floating share count of 53.12M. Insiders hold about 5.46% of the company’s shares, while institutions hold 102.20% stake in the company. Shares short for RGEN as of 1752537600 were 3398315 with a Short Ratio of 4.14, compared to 1749772800 on 3391049. Therefore, it implies a Short% of Shares Outstanding of 3398315 and a Short% of Float of 8.1599995.
Earnings Estimates
A detailed examination of Repligen Corp (RGEN) is currently in progress, with 17.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.5, with high estimates of $0.57 and low estimates of $0.44.
Analysts are recommending an EPS of between $1.77 and $1.65 for the fiscal current year, implying an average EPS of $1.69. EPS for the following year is $2.18, with 18.0 analysts recommending between $2.38 and $1.87.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 17 analysts. It ranges from a high estimate of $185.7M to a low estimate of $180M. As of the current estimate, Repligen Corp’s year-ago sales were $154.87MFor the next quarter, 17 analysts are estimating revenue of $193.2M. There is a high estimate of $200.5M for the next quarter, whereas the lowest estimate is $185.03M.
A total of 18 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $734.8M, while the lowest revenue estimate was $720.5M, resulting in an average revenue estimate of $727.19M. In the same quarter a year ago, actual revenue was $634.44MBased on 19 analysts’ estimates, the company’s revenue will be $826.21M in the next fiscal year. The high estimate is $850M and the low estimate is $789.14M.
